Related Experiment Videos
Tigecycline: a novel glycylcycline
Ethan Rubinstein1, David Vaughan
1Section of Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada. erubins@yahoo.com
Drugs
|June 28, 2005
Summary
Tigecycline, a novel glycylcycline antibacterial, shows potent activity against multidrug-resistant pathogens. Clinical trials demonstrate its efficacy in treating serious infections with manageable side effects, supporting its role in combating bacterial resistance.
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Bacterial resistance to existing antibacterials is a growing global health concern.
- Tigecycline represents a new class of antibacterials, glycylcyclines, developed to address this challenge.
- Multidrug-resistant pathogens pose a significant threat in both hospital and community settings.
Purpose of the Study:
- To evaluate the efficacy and safety of tigecycline, a novel glycylcycline antibacterial.
- To assess tigecycline's activity against a broad spectrum of clinically relevant pathogens, including resistant strains.
- To understand the pharmacokinetic and pharmacodynamic properties of tigecycline.
Main Methods:
- Phase III human clinical trials were conducted to assess therapeutic response.
- Microbiological activity was evaluated against various Gram-positive, Gram-negative, and anaerobic pathogens.
- Animal infection models were used to study efficacy in conditions like pneumonia and peritonitis.
- Pharmacokinetic parameters including volume of distribution, clearance, and half-life were determined.
Main Results:
- Tigecycline demonstrated potent activity against susceptible and multidrug-resistant staphylococci, enterococci, streptococci, Enterobacteriaceae, and anaerobic pathogens.
- Phase III trials showed excellent therapeutic response in intra-abdominal and skin/soft tissue infections.
- Nausea and vomiting were the most common adverse events, comparable to other tetracyclines.
- Efficacy was confirmed in various animal infection models.
Conclusions:
- Tigecycline exhibits a favorable efficacy and safety profile for treating complex infections.
- Its broad spectrum of activity, including against resistant pathogens, makes it a valuable therapeutic option.
- Pharmacokinetic data and correlation of time above minimum inhibitory concentration with bacterial eradication support its clinical development.
- Tigecycline is a promising empirical parenteral treatment for challenging nosocomial and community-acquired infections.